---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-26-000014"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:34:57.025760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M

## Summary
- Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).
- Q4 net sales $33.8M (+16% YoY); Q4 net income $4.1M vs $7.2M prior; Q4 adjusted EBITDA $4.1M (+$0.7M).
- Gross margin improved 250 bps to 64.3% for year; cash $64.8M at Dec 31, 2025.
- FY 2026 net sales outlook 10-15% growth ex. reference standards segment sold in Feb 2026 for ~$6M.
- Acquired foundational NR patent portfolio from Queen’s University Belfast (Dec 2025); launched Tru Niagen Beauty (Nov 2025).

## SEC filing metadata
- accession: 0001386570-26-000014
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000014/0001386570-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000014/cdxc-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-26-000014
- JSON: https://secwatch.observer/filing/0001386570-26-000014.json
- Plain text: https://secwatch.observer/filing/0001386570-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.